Skip to content

Study · Randomized controlled trial · 2019

6 results

One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.

Svensson CK, Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Koyuncu K, Schjerning O, Nielsen J, Ekstrøm CT, Correll CU, Vilsbøll T, Fink-Jensen A

Acta psychiatrica Scandinavica28 Nov 2018Cited by 48 (Europe PMC)

PMID30374965 (opens in a new tab)DOI10.1111/acps.12982 (opens in a new tab)PepBankPUB-30374965
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In prediabetic, overweight or obese patients with schizophrenia-spectrum disorder, body weight increased in the liraglutide-treated group from end of treatment to the 1-year follow-up.

    In plain wordsIn people on clozapine or olanzapine, body weight rose again in the year after liraglutide treatment ended.

    Peptide
    Liraglutide
    Outcome
    IncreaseBody weight change from end of treatment to 1-year follow-up
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    From end of treatment to the 1-year follow-up, body weight had increased in the liraglutide-treated group.
    2 context sentences
    Summary · context
    In a randomized trial, we previously demonstrated that 16 weeks of glucagon-like peptide-1 receptor agonist liraglutide treatment vs. placebo significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine.
    Summary · context
    One year after completion of the intervention, we investigated changes in body weight, fasting glucose, glycated hemoglobin, C-peptide, and lipids comparing 1-year follow-up levels to end of treatment (week 16) and baseline (week 0) levels.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In prediabetic, overweight or obese patients with schizophrenia-spectrum disorder, placebo-subtracted body weight remained significantly lower than baseline 1 year after liraglutide treatment stopped.

    In plain wordsIn people on clozapine or olanzapine, some of the weight loss from liraglutide, compared with placebo, was still present 1 year after treatment stopped.

    Peptide
    Liraglutide
    Outcome
    DecreasePlacebo-subtracted body weight change at 1-year follow-up versus baseline
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    Placebo-subtracted body weight change
    −3.8 kg
    1-year follow-up versus baseline

    Source sentences

    Summary
    However, compared to baseline levels, the placebo-subtracted body weight loss remained significantly reduced (-3.8 kg, 95% CI: -7.3 to -0.2, P = 0.04).
    2 context sentences
    Summary · context
    In a randomized trial, we previously demonstrated that 16 weeks of glucagon-like peptide-1 receptor agonist liraglutide treatment vs. placebo significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine.
    Summary · context
    One year after completion of the intervention, we investigated changes in body weight, fasting glucose, glycated hemoglobin, C-peptide, and lipids comparing 1-year follow-up levels to end of treatment (week 16) and baseline (week 0) levels.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In prediabetic, overweight or obese patients with schizophrenia-spectrum disorder, fasting glucose had returned to baseline levels 1 year after stopping liraglutide.

    In plain wordsIn people on clozapine or olanzapine, fasting glucose was back at its starting level 1 year after liraglutide stopped.

    Peptide
    Liraglutide
    Outcome
    No significant changeFasting glucose at 1-year follow-up versus baseline
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Fasting glucose, glycated hemoglobin, C-peptide, and lipids had each returned to baseline levels 1 year after stopping liraglutide.
    2 context sentences
    Summary · context
    In a randomized trial, we previously demonstrated that 16 weeks of glucagon-like peptide-1 receptor agonist liraglutide treatment vs. placebo significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine.
    Summary · context
    One year after completion of the intervention, we investigated changes in body weight, fasting glucose, glycated hemoglobin, C-peptide, and lipids comparing 1-year follow-up levels to end of treatment (week 16) and baseline (week 0) levels.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In prediabetic, overweight or obese patients with schizophrenia-spectrum disorder, glycated hemoglobin had returned to baseline levels 1 year after stopping liraglutide.

    In plain wordsIn people on clozapine or olanzapine, glycated hemoglobin was back at its starting level 1 year after liraglutide stopped.

    Peptide
    Liraglutide
    Outcome
    No significant changeGlycated hemoglobin at 1-year follow-up versus baseline
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Fasting glucose, glycated hemoglobin, C-peptide, and lipids had each returned to baseline levels 1 year after stopping liraglutide.
    2 context sentences
    Summary · context
    In a randomized trial, we previously demonstrated that 16 weeks of glucagon-like peptide-1 receptor agonist liraglutide treatment vs. placebo significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine.
    Summary · context
    One year after completion of the intervention, we investigated changes in body weight, fasting glucose, glycated hemoglobin, C-peptide, and lipids comparing 1-year follow-up levels to end of treatment (week 16) and baseline (week 0) levels.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In prediabetic, overweight or obese patients with schizophrenia-spectrum disorder, C-peptide had returned to baseline levels 1 year after stopping liraglutide.

    In plain wordsIn people on clozapine or olanzapine, C-peptide was back at its starting level 1 year after liraglutide stopped.

    Peptide
    Liraglutide
    Outcome
    No significant changeC-peptide at 1-year follow-up versus baseline
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Fasting glucose, glycated hemoglobin, C-peptide, and lipids had each returned to baseline levels 1 year after stopping liraglutide.
    2 context sentences
    Summary · context
    In a randomized trial, we previously demonstrated that 16 weeks of glucagon-like peptide-1 receptor agonist liraglutide treatment vs. placebo significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine.
    Summary · context
    One year after completion of the intervention, we investigated changes in body weight, fasting glucose, glycated hemoglobin, C-peptide, and lipids comparing 1-year follow-up levels to end of treatment (week 16) and baseline (week 0) levels.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In prediabetic, overweight or obese patients with schizophrenia-spectrum disorder, lipids had returned to baseline levels 1 year after stopping liraglutide.

    In plain wordsIn people on clozapine or olanzapine, blood fats were back at their starting levels 1 year after liraglutide stopped.

    Peptide
    Liraglutide
    Outcome
    No significant changeLipids at 1-year follow-up versus baseline
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Fasting glucose, glycated hemoglobin, C-peptide, and lipids had each returned to baseline levels 1 year after stopping liraglutide.
    2 context sentences
    Summary · context
    In a randomized trial, we previously demonstrated that 16 weeks of glucagon-like peptide-1 receptor agonist liraglutide treatment vs. placebo significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine.
    Summary · context
    One year after completion of the intervention, we investigated changes in body weight, fasting glucose, glycated hemoglobin, C-peptide, and lipids comparing 1-year follow-up levels to end of treatment (week 16) and baseline (week 0) levels.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.